Compare Stocks: RNAC, SANA, SLDB, and LXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$2.06 -5.5%	$2.26	$1.10 ▼ $2.68	$970M	1.02	2.65 million shs	3.17 million shs
RNAC Cartesian Therapeutics	$7.87 -2.6%	$8.66	$5.60 ▼ $11.00	$244.46M	0.62	103,805 shs	117,045 shs
SANA Sana Biotechnology	$3.08 -7.5%	$3.48	$2.61 ▼ $6.55	$922.03M	2.12	3.59 million shs	3.84 million shs
SLDB Solid Biosciences	$8.02 -10.1%	$8.96	$3.79 ▼ $11.45	$956.45M	2.44	1.09 million shs	1.09 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	-5.50%	+1.98%	-11.21%	-10.04%	+70.25%
RNAC Cartesian Therapeutics	-2.60%	-0.51%	-21.77%	-11.87%	-19.78%
SANA Sana Biotechnology	-7.51%	+5.48%	-18.52%	-5.52%	-5.52%
SLDB Solid Biosciences	-10.09%	-8.03%	-12.45%	-9.48%	+50.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$2.06 -5.5%	$2.26	$1.10 ▼ $2.68	$970M	1.02	2.65 million shs	3.17 million shs
RNAC Cartesian Therapeutics	$7.87 -2.6%	$8.66	$5.60 ▼ $11.00	$244.46M	0.62	103,805 shs	117,045 shs
SANA Sana Biotechnology	$3.08 -7.5%	$3.48	$2.61 ▼ $6.55	$922.03M	2.12	3.59 million shs	3.84 million shs
SLDB Solid Biosciences	$8.02 -10.1%	$8.96	$3.79 ▼ $11.45	$956.45M	2.44	1.09 million shs	1.09 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	-5.50%	+1.98%	-11.21%	-10.04%	+70.25%
RNAC Cartesian Therapeutics	-2.60%	-0.51%	-21.77%	-11.87%	-19.78%
SANA Sana Biotechnology	-7.51%	+5.48%	-18.52%	-5.52%	-5.52%
SLDB Solid Biosciences	-10.09%	-8.03%	-12.45%	-9.48%	+50.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	120.87% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	314.23% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	203.03% Upside
SLDB Solid Biosciences	2.85	Moderate Buy	$18.69	133.07% Upside

Current Analyst Ratings Breakdown

Latest RNAC, SANA, SLDB, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/16/2026	SLDB Solid Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
9/14/2026	SLDB Solid Biosciences	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/14/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/9/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXRX Lexicon Pharmaceuticals	$49.80M	18.41	N/A	N/A	$0.30 per share	6.87
RNAC Cartesian Therapeutics	$2.80M	85.02	N/A	N/A	($4.85) per share	-1.62
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest RNAC, SANA, SLDB, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
RNAC Cartesian Therapeutics	N/A	7.48	7.48
SANA Sana Biotechnology	N/A	1.38	1.38
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXRX Lexicon Pharmaceuticals	74.70%
RNAC Cartesian Therapeutics	86.95%
SANA Sana Biotechnology	88.23%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
LXRX Lexicon Pharmaceuticals	14.00%
RNAC Cartesian Therapeutics	37.20%
SANA Sana Biotechnology	25.40%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable
RNAC Cartesian Therapeutics	75	30.25 million	19.00 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable
SLDB Solid Biosciences	121	107.22 million	104.37 million	Optionable

RNAC, SANA, SLDB, and LXRX Headlines

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Trading Down 10% - Time to Sell?

September 23 at 2:59 PM | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns Outperform Rating from Analysts at Royal Bank Of Canada

September 19, 2026 | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) Upgraded to Moderate Buy at Royal Bank Of Canada

September 17, 2026 | marketbeat.com

RBC Capital initiates coverage of Solid Biosciences at outperform

September 17, 2026 | msn.com

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

September 16, 2026 | finance.yahoo.com

Solid Biosciences wins new Outperform at RBC on DMD opportunity

September 16, 2026 | seekingalpha.com

Solid Biosciences (NASDAQ:SLDB) Shares Down 6.4% - Time to Sell?

September 15, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright

September 14, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Analysts

September 14, 2026 | marketbeat.com

Solid Biosciences (SLDB) Gets a Buy from Citi

September 12, 2026 | theglobeandmail.com

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

243,154 Shares in Solid Biosciences Inc. $SLDB Purchased by Bank of New York Mellon Corp

September 8, 2026 | marketbeat.com

Solid Biosciences to Participate at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $26.00 at Cantor Fitzgerald

August 27, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading 5.5% Higher - Should You Buy?

August 25, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, SANA, SLDB, and LXRX Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.06 -0.12 (-5.50%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.04 -0.02 (-1.21%)

As of 07:01 AM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Cartesian Therapeutics NASDAQ:RNAC

$7.87 -0.21 (-2.60%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$7.86 -0.01 (-0.19%)

As of 09/23/2026 07:30 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Sana Biotechnology NASDAQ:SANA

$3.08 -0.25 (-7.51%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.08 +0.00 (+0.13%)

As of 07:34 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Solid Biosciences NASDAQ:SLDB

$8.02 -0.90 (-10.09%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$8.07 +0.05 (+0.61%)

As of 07:35 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAC, SANA, SLDB, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAC, SANA, SLDB, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAC, SANA, SLDB, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, SANA, SLDB, and LXRX Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

Cartesian Therapeutics NASDAQ:RNAC

Sana Biotechnology NASDAQ:SANA

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAC, SANA, SLDB, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAC, SANA, SLDB, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAC, SANA, SLDB, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, SANA, SLDB, and LXRX Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

Cartesian Therapeutics NASDAQ:RNAC

Sana Biotechnology NASDAQ:SANA

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools